Classic hairy cell leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:58017C91.4
Who is this for?
Show terms as
2FDA treatments19Active trials33Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Classic hairy cell leukemia (HCL) is a rare, slow-growing type of blood cancer that affects a type of white blood cell called B lymphocytes. The name comes from the way the cancer cells look under a microscope — they have tiny hair-like projections on their surface. HCL is sometimes called hairy cell leukemia classic type to distinguish it from a rarer variant form. The disease causes the bone marrow to fill up with abnormal cells, which crowds out healthy blood cells and leads to low counts of red blood cells, white blood cells, and platelets. Because of these low blood counts, people with HCL often feel very tired, get infections easily, and may bleed or bruise more than usual. The spleen — an organ in the upper left belly — often becomes enlarged, which can cause discomfort or a feeling of fullness. Many people are diagnosed after a routine blood test shows abnormal results, even before they feel very sick. The good news is that HCL responds very well to treatment. Most people achieve long-lasting remission — meaning the cancer goes away or becomes undetectable — with a single course of chemotherapy. The most commonly used treatments are drugs called cladribine and pentostatin. While HCL is not usually considered curable in the traditional sense, many patients live for decades with excellent quality of life after treatment.

Also known as:

Key symptoms:

Extreme tiredness and fatigueFrequent or unusual infectionsEasy bruising or bleedingEnlarged spleen causing left-sided belly discomfort or fullnessFeeling full quickly when eatingUnexplained weight lossNight sweatsPale skinSwollen lymph nodes (less common)Weakness and low energy

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI) — PHASE1, PHASE2

TrialRECRUITING
Jan 2026Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd. — PHASE1, PHASE2

TrialRECRUITING
Dec 2025Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

David K Carroll — PHASE1, PHASE2

TrialRECRUITING
Jan 2025Assessment of Disease Burden in Hairy Cell Leukemia

IRCCS Azienda Ospedaliero-Universitaria di Bologna — NA

TrialRECRUITING
Dec 2024Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING
Dec 2024Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

IRCCS Azienda Ospedaliero-Universitaria di Bologna

TrialRECRUITING
Dec 2024Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management

IRCCS Azienda Ospedaliero-Universitaria di Bologna

TrialRECRUITING
Sep 2024A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Memorial Sloan Kettering Cancer Center — PHASE2

TrialRECRUITING
Jun 2024Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Power Life Sciences Inc.

TrialNOT YET RECRUITING
Mar 2024AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

LUMOXITI

moxetumomab pasudotox-tdfk· AstraZeneca Pharmaceuticals LPOrphan Drug
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nu

LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Nipent

pentostatin for injection· SuperGen, Inc.■ Boxed WarningOrphan Drug

Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.

Clinical Trials

19 recruitingView all trials with filters →
Phase 210 trials
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Phase 2
Active
PI: Jae Park, MD (Memorial Sloan Kettering Cancer Center) · Sites: New Haven, Connecticut; Boston, Massachusetts +7 more · Age: 1899 yrs
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Phase 2
Actively Recruiting
PI: Robert J Kreitman (National Cancer Institute LAO) · Sites: Duarte, California; Irvine, California +19 more · Age: 1899 yrs
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Phase 2
Active
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Phase 2
Actively Recruiting
PI: Jae Park, MD (Memorial Sloan Kettering Cancer Center) · Sites: Boston, Massachusetts; Rochester, Minnesota +8 more · Age: 1899 yrs
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Phase 2
Actively Recruiting
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Phase 2
Actively Recruiting
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Phase 2
Active
PI: Kerry A Rogers (Ohio State University Comprehensive Cancer Center) · Sites: Bethesda, Maryland; Detroit, Michigan +3 more · Age: 1899 yrs
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Phase 2
Actively Recruiting
PI: Farhad Ravandi-Kashani (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Phase 2
Active
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Phase 2
Active
PI: Alan Saven, MD (Scripps Clinic) · Sites: La Jolla, California · Age: 1890 yrs
Phase 13 trials
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Phase 1
Actively Recruiting
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Phase 1
Active
PI: Robert J Kreitman, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1
Actively Recruiting
PI: Matthew Frank, MD, PhD (Stanford University) · Sites: Palo Alto, California · Age: 1899 yrs
N/A1 trial
Assessment of Disease Burden in Hairy Cell Leukemia
N/A
Actively Recruiting
PI: Pier Luigi Zinzani, MD (IRCCS Azienda Ospedaliero-Universitaria di Bologna) · Sites: Bologna, Bologna · Age: 1899 yrs
Other3 trials
Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
Actively Recruiting
PI: Lucia Catani, PhD (IRCCS Azienda Ospedaliero-Universitaria di Bologna) · Sites: Palermo, PA; Siena, SI +1 more · Age: 1899 yrs
Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Actively Recruiting
PI: Lucia Catani, PhD (IRCCS Azienda Ospedaliero-Universitaria di Bologna) · Sites: Bologna · Age: 1899 yrs
Hairy Cell Leukemia Patient Data Registry
Actively Recruiting
PI: Michael Grever, MD (The Ohio State University Comprehensive Cancer Cen) · Sites: Miami, Florida; Rochester, Minnesota +4 more · Age: 1899 yrs

Specialists

Showing 25 of 33View all specialists →
RK
Robert J Kreitman
OLNEY, MD
Specialist
PI on 1 active trial1 Classic hairy cell leukemia publication
MD
Mathias J Rummel, Prof. Dr.
COLORADO SPRINGS, CO
Specialist
PI on 2 active trials
FR
Farhad Ravandi-Kashani
HOUSTON, TX
Specialist
PI on 7 active trials2 Classic hairy cell leukemia publications
RM
Robert J Kreitman, M.D.
OLNEY, MD
Specialist
PI on 12 active trials
MM
Michael E. Rytting, MD
EL PASO, TX
Specialist
PI on 3 active trials
TS
Tanya Siddiqi
DUARTE, CA
Specialist
PI on 3 active trials10 Classic hairy cell leukemia publications
YM
Yasuhiro Oki, MD
HOUSTON, TX
Specialist
PI on 4 active trials
SB
Seema A Bhat
COLUMBUS, OH
Specialist
PI on 1 active trial
VP
Vassiliki Papadimitrakopoulou
HOUSTON, TX
Specialist
PI on 10 active trials1 Classic hairy cell leukemia publication
KK
Karen Kelly
Specialist
PI on 2 active trials28 Classic hairy cell leukemia publications
MK
Marina Konopleva
HOUSTON, TX
Specialist
PI on 2 active trials
RZ
Reinhard Zenhaeusern
Specialist
PI on 2 active trials
MF
Matthew Frank
Specialist
PI on 2 active trials
LP
Loann C. Peterson
CHICAGO, IL
Specialist
PI on 1 active trial
JP
Jae H. Park
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
LUMOXITI(moxetumomab pasudotox-tdfk)AstraZeneca Pharmaceuticals LP

Leustatin Injection

R. W. Johnson Pharmaceutical Research Institute

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Classic hairy cell leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Classic hairy cell leukemiaForum →

No community posts yet. Be the first to share your experience with Classic hairy cell leukemia.

Start the conversation →

Latest news about Classic hairy cell leukemia

Disease timeline:

New recruiting trial: Hairy Cell Leukemia Patient Data Registry

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

A new clinical trial is recruiting patients for Classic hairy cell leukemia

New recruiting trial: Assessment of Disease Burden in Hairy Cell Leukemia

A new clinical trial is recruiting patients for Classic hairy cell leukemia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which treatment do you recommend for me, and why — cladribine or pentostatin?,How will we know if the treatment is working, and what does remission look like for my case?,What are the most common side effects of treatment, and how can I manage them?,How often will I need blood tests and check-ups after treatment?,What signs should I watch for that might mean the disease has come back?,Are there any clinical trials I should consider?,Are there any vaccines or medications I should avoid because of my weakened immune system?

Common questions about Classic hairy cell leukemia

What is Classic hairy cell leukemia?

Classic hairy cell leukemia (HCL) is a rare, slow-growing type of blood cancer that affects a type of white blood cell called B lymphocytes. The name comes from the way the cancer cells look under a microscope — they have tiny hair-like projections on their surface. HCL is sometimes called hairy cell leukemia classic type to distinguish it from a rarer variant form. The disease causes the bone marrow to fill up with abnormal cells, which crowds out healthy blood cells and leads to low counts of red blood cells, white blood cells, and platelets. Because of these low blood counts, people with H

How is Classic hairy cell leukemia inherited?

Classic hairy cell leukemia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Classic hairy cell leukemia typically begin?

Typical onset of Classic hairy cell leukemia is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Classic hairy cell leukemia?

Yes — 19 recruiting clinical trials are currently listed for Classic hairy cell leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Classic hairy cell leukemia?

25 specialists and care centers treating Classic hairy cell leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Classic hairy cell leukemia?

3 patient support programs are currently tracked on UniteRare for Classic hairy cell leukemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.